Heshmatpour Amir F purchased $50K of NTHI

Heshmatpour Amir F (CEO, President) purchased 9,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at $5.54 on 2026-08-18.

Original reporting
SEC EDGAR · Heshmatpour Amir F
Published Aug 18, 2026, 6:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 6:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTHI
Bullish
low confidence
Mentioned
$NTHI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTHIBullishLow
01

Why it matters

The disclosed open-market purchase by the CEO/President is a new, primary-source datapoint but does not include any new company fundamentals (guidance, contracts, litigation, or financial results).

02

Market read

Traders may note the insider buying as a small sentiment input, but it is unlikely to drive a durable repricing without additional company catalysts.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide context on total insider holdings changes beyond the post-transaction share count.

Relevance 4/10Novelty 3/10Timing: today’s SEC Form 4 filing (2026-08-18)

Background

The article is an SEC Form 4 insider transaction disclosure for NEONC Technologies Holdings, Inc.

Company-level read

Ticker impact

$NTHIBullishLow confidence
Context

SEC Form 4 shows CEO/President Heshmatpour Amir F bought 9,000 shares of NEONC Technologies Holdings at $5.54 on 2026-08-18.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and should fade unless followed by larger actions or company-specific news.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying operational or financial disclosure in the text.

Market effects

No sector-level implications are provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by diversification, liquidity needs, or routine compensation-related behavior, so the signal may be weak.

Key entities

  • NEONC Technologies Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Heshmatpour Amir F

    CEO, President, and 10% owner who purchased shares on 2026-08-18.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTHIMedAI 8/10

NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data to be presented at the Society for Neuro-Oncology Annual Meeting on November 13 CALABASAS, Calif., Nov.

$NTHIMedAI 8/10

NeOnc to Present NEO100 and NEO212 Data at Neuro-Oncology Meeting

NeOnc Technologies (NTHI) will present data on its NEO100 and NEO212 programs at the Society for Neuro-Oncology meeting. NEO100 data includes Phase 1/2a study and compassionate use results for recurrent IDH1-mutant astrocytoma. NEO212 data covers Phase 1 safety, pharmacokinetics, and early activity signals in TMZ-resistant recurrent GBM and brain metastases. Both posters are scheduled for November 13, 2026.

$NTHILowAI 8/10

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi Treating physicians report that a critically ill three-year-old boy is breathing independently and showing renewed movement following initiation of invest